Weekly Recap: Jefferies Buy rating and Absci joins three conferences

What happened

Jefferies initiated coverage of Absci Corporation with a Buy rating and a $14 price target. Absci plans to take part in fireside chats at three healthcare investor conferences: Guggenheim on Nov. 10, Jefferies on Nov. 18, and Evercore on Dec. 1, 2026.

Confirmed

Global impact / market context

The Buy rating and $14 target give investors Jefferies’ view of Absci’s potential value, while the conference appearances create opportunities for the company to discuss its business with investors. Any effect on demand for its shares or its ability to raise funds is not reported.

Analyst inference

The update combines an analyst opinion with scheduled investor meetings; it does not report new financial results, contracts, or operating changes. The conference dates are in November and December 2026, so the article describes future events rather than completed meetings.

Analyst inference

What to watch

1. Jefferies’ $14 price target and Buy rating are its stated assessment, not a reported share price or a guarantee of future performance. Confirmed
2. Absci is scheduled to join the Guggenheim, Jefferies, and Evercore healthcare investor conference fireside chats on the dates listed in 2026. Confirmed
3. If Absci shares new business or funding details at the conferences, investors could reassess the company’s prospects; the article gives no indication that such disclosures are planned. Analyst inference

Evidence

• Original source link unavailable